Literature DB >> 31408245

A novel RBMX-TFE3 gene fusion in a highly aggressive pediatric renal perivascular epithelioid cell tumor.

Pedram Argani1,2, Lei Zhang3, Yun-Shao Sung3, Marissa J White1, Karin Miller1, Mark Hopkins1, Donald Small2, Christine A Pratilas2, David Swanson4, Brendan Dickson4, Cristina R Antonescu3.   

Abstract

We report an Xp11 translocation perivascular epithelioid cell tumor (PEComa) with a novel RBMX-TFE3 gene fusion, resulting from a paracentric X chromosome inversion, inv(X)(p11;q26). The neoplasm occurred in an otherwise healthy 12-year-old boy who presented with a large left renal mass with extension into the inferior vena cava. The patient was found to have multiple pulmonary metastases at diagnosis and died of disease 3 months later. The morphology (epithelioid clear cells with alveolar and nested architecture) and immunophenotype (TFE3 and HMB45 strongly positive; actin, desmin, and PAX8 negative) was typical of an Xp11 translocation PEComa; however, TFE3 rearrangement was initially not detected by routine TFE3 break-apart fluorescence in situ hybridization (FISH). Further RNA sequencing revealed a novel RBMX-TFE3 gene fusion, which was subsequently confirmed by fusion assay FISH, using custom design RBMX and TFE3 come-together probes. This report describes a novel TFE3 gene fusion partner, RBMX, in a pediatric renal PEComa patient associated with a fulminant clinical course. As documented in other intrachromosomal Xp11.2 inversions, such as fusions with NONO, RBM10, or GRIPAP1 genes, the TFE3 break-apart might be below the FISH resolution, resulting in a false negative result.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  TFE3; renal neoplasm; translocation

Year:  2019        PMID: 31408245      PMCID: PMC7057291          DOI: 10.1002/gcc.22801

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  25 in total

1.  Identification of a novel PARP14-TFE3 gene fusion from 10-year-old FFPE tissue by RNA-seq.

Authors:  Weihua Huang; Michael Goldfischer; Sabina Babayeva; Yong Mao; Konstantin Volyanskyy; Nevenka Dimitrova; John T Fallon; Minghao Zhong
Journal:  Genes Chromosomes Cancer       Date:  2015-05-29       Impact factor: 5.006

2.  RBMX is a component of the centromere noncoding RNP complex involved in cohesion regulation.

Authors:  Yukiko Cho; Takashi Ideue; Megumi Nagayama; Norie Araki; Tokio Tani
Journal:  Genes Cells       Date:  2018-01-31       Impact factor: 1.891

3.  Melanotic Translocation Renal Cell Carcinoma With a Novel ARID1B-TFE3 Gene Fusion.

Authors:  Tatjana Antic; Jerome B Taxy; Mir Alikhan; Jeremy Segal
Journal:  Am J Surg Pathol       Date:  2017-11       Impact factor: 6.394

4.  Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.

Authors:  Marion Classe; Gabriel G Malouf; Xiaoping Su; Hui Yao; Erika J Thompson; Denaha J Doss; Valérie Grégoire; Julien Lenobin; Jean-Christophe Fantoni; Hélène Sudour-Bonnange; David Khayat; Sébastien Aubert; Nizar M Tannir; Xavier Leroy
Journal:  Histopathology       Date:  2017-03-21       Impact factor: 5.087

5.  RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH.

Authors:  Pedram Argani; Lei Zhang; Victor E Reuter; Satish K Tickoo; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2017-05       Impact factor: 6.394

6.  Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR.

Authors:  Pedram Argani; Marick Laé; Brian Hutchinson; Victor E Reuter; Margaret H Collins; John Perentesis; John E Tomaszewski; John S J Brooks; Geza Acs; Julia A Bridge; Sara O Vargas; Ian J Davis; David E Fisher; Marc Ladanyi
Journal:  Am J Surg Pathol       Date:  2005-02       Impact factor: 6.394

7.  TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.

Authors:  Pedram Argani; Minghao Zhong; Victor E Reuter; John T Fallon; Jonathan I Epstein; George J Netto; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-06       Impact factor: 6.394

8.  A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23).

Authors:  Pedram Argani; Man Yee Lui; Jérôme Couturier; Raymonde Bouvier; Jean-Christophe Fournet; Marc Ladanyi
Journal:  Oncogene       Date:  2003-08-14       Impact factor: 9.867

9.  Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma.

Authors:  Cristina R Antonescu; Francois Le Loarer; Juan-Miguel Mosquera; Andrea Sboner; Lei Zhang; Chun-Liang Chen; Hsiao-Wei Chen; Nursat Pathan; Thomas Krausz; Brendan C Dickson; Ilan Weinreb; Mark A Rubin; Meera Hameed; Christopher D M Fletcher
Journal:  Genes Chromosomes Cancer       Date:  2013-06-05       Impact factor: 5.006

10.  RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.

Authors:  Xiao-Tong Wang; Qiu-Yuan Xia; Sheng-Bing Ye; Xuan Wang; Rui Li; Ru Fang; Shan-Shan Shi; Ru-Song Zhang; Xiao Tan; Jie-Yu Chen; Ke Sun; Xiao-Dong Teng; Heng-Hui Ma; Zhen-Feng Lu; Xiao-Jun Zhou; Qiu Rao
Journal:  Mod Pathol       Date:  2018-04-30       Impact factor: 7.842

View more
  3 in total

Review 1.  A review of neoplasms with MITF/MiT family translocations.

Authors:  Shuanzeng Wei; Joseph R Testa; Pedram Argani
Journal:  Histol Histopathol       Date:  2022-02-02       Impact factor: 2.303

Review 2.  MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.

Authors:  Audrey Simonaggio; Damien Ambrosetti; Virginie Verkarre; Marie Auvray; Stéphane Oudard; Yann-Alexandre Vano
Journal:  Int J Mol Sci       Date:  2022-07-11       Impact factor: 6.208

3.  Comprehensive Analysis of Co-Mutations Identifies Cooperating Mechanisms of Tumorigenesis.

Authors:  Limin Jiang; Hui Yu; Scott Ness; Peng Mao; Fei Guo; Jijun Tang; Yan Guo
Journal:  Cancers (Basel)       Date:  2022-01-14       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.